Candel Therapeutics, Inc.
CADL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.10 | -0.04 | -0.26 |
| FCF Yield | -3.71% | -3.42% | -4.82% | -1.88% |
| EV / EBITDA | -15.09 | -38.95 | 12.32 | -16.34 |
| Quality | ||||
| ROIC | 0.00% | -11.34% | -9.50% | -10.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -24.50% |
| Cash Conversion Ratio | 0.91 | 1.85 | -1.17 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -16.34% | -3.52% | -48.17% | 11.50% |
| Safety | ||||
| Net Debt / EBITDA | 6.11 | 21.39 | -10.25 | 6.64 |
| Interest Coverage | 82.03 | -47.36 | -26.57 | -20.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -726.32 | -279.18 | -87.06 |